Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Weingarten

Interventional Pain Medicine Syosset, NY Medical Doctor

NPI 1558353078 CMS profile 24637

121 Eileen Way, Syosset, NY 11791

Open in the dashboard

General payments

$42,520

1,888 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Weingarten of Syosset, NY is reported in the CMS Open Payments database as having received $42,520 across 1,888 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,812 255
2024 General $3,729 251
2023 General $3,776 249
2022 General $3,155 208
2021 General $7,761 355
2020 General $3,890 247
2019 General $15,396 323

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Weingarten
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alexander Weingarten were reported at $4,812. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alexander Weingarten Interventional Pain Medicine median Middle half National median
2019 $15,396 $684 $216–$2,079 $163
2020 $3,890 $382 $122–$1,109 $114
2021 $7,761 $552 $167–$1,554 $132
2022 $3,155 $605 $187–$1,924 $149
2023 $3,776 $671 $195–$1,915 $160
2024 $3,729 $684 $206–$1,837 $164
2025 $4,812 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. US WorldMeds, LLC $7,225 43 payments
  2. West Therapeutics Development, LLC $5,056 5 payments
  3. Collegium Pharmaceutical, Inc. $3,229 215 payments
  4. AbbVie, Inc. $2,597 153 payments
  5. Scilex Pharmaceuticals Inc. $2,336 143 payments
  6. Regeneron Pharmaceuticals, Inc. $1,860 1 payment
  7. Biodelivery Sciences International, Inc. $1,798 141 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $1,459 121 payments
  9. Biohaven Pharmaceuticals, Inc. $1,425 15 payments
  10. Protega Pharmaceutials LLC $1,360 16 payments
  11. Other $14,175 1,035 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $26,149 1,860 payments
  2. Consulting Fee $7,990 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,000 2 payments
  4. Honoraria $1,750 2 payments
  5. Travel and Lodging $1,589 7 payments
  6. Education $42 10 payments
  7. Gift $0 4 payments
Products named General payments · program years 2019–2025
  1. Lucemyra/Lofexidine $7,133 33 payments
  2. Lazanda $5,056 5 payments
  3. XTAMPZA $1,902 141 payments
  4. ZTLido $1,884 115 payments
  5. UBRELVY $1,862 111 payments
  6. NURTEC ODT $1,798 40 payments
  7. BELBUCA Chronic Pain $1,529 103 payments
  8. ROXYBOND $1,360 16 payments
  9. QULIPTA $1,321 76 payments
  10. BELBUCA Opioid Analgesic $1,312 73 payments
  11. Other $22,501 1,651 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

10,965

Median for Interventional Pain Management: 1,220

Drug cost

$3,162,327

Median for Interventional Pain Management: $39,344

Branded share of claims

32.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Budesonide Er Budesonide Brand 172 $529,737
Oxycontin Oxycodone Hcl Brand 247 $322,401
Levorphanol Tartrate Generic 119 $308,055
Nucynta Er Tapentadol Hcl Brand 250 $275,935
Diclofenac Sodium Generic 217 $185,179
Diclofenac Potassium Generic 458 $138,643
Xtampza Er Oxycodone Myristate Brand 132 $117,227
Roxybond Oxycodone Hcl Brand 59 $97,161
Relistor Methylnaltrexone Bromide Brand 32 $97,109
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 709 $94,952

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$810,273

Of which drugs: $28,410

Medicare patients

547

Average age 69

Services billed

30,145

291 women, 256 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 64%
Diabetes 35%
Ischemic heart disease 33%
Depression 32%
COPD 22%
Chronic kidney disease 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 179 20,064 $2,055
Injection, methylprednisolone acetate, 80 mg J1040 Office 43 56 $430
Injection, methylprednisolone acetate, 40 mg J1030 Office 53 66 $282
Injection, methylprednisolone acetate, 20 mg J1020 Office 15 16 $70
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 114 212 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
$455 132 —
ZTLido
$449 101 —
BELBUCA
$381 98 —
MOVANTIK
$337 138 —
UBRELVY
$259 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,888 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record